Research Article

Synergistic Antitumor Effect of Doxorubicin and Tacrolimus (FK506) on Hepatocellular Carcinoma Cell Lines

Francesca Capone,1 Eliana Guerriero,1 Angela Sorice,1 Giovanni Colonna,2 Gabriella Storti,3 Jessica Pagliuca,1 Giuseppe Castello,1 and Susan Costantini1

1 Istituto Nazionale per lo Studio E la Cura dei Tumori “Fondazione Giovanni Pascale”, IRCCS, 80131 Naples, Italy
2 Biochemistry, Biophysics and General Pathology Department, Second University of Naples, 80138 Naples, Italy
3 Department of Onco-Hematology, S.G. Moscati Hospital, 83100 Avellino, Italy

Correspondence should be addressed to Susan Costantini; s.costantini@istitutotumori.na.it

Received 5 November 2013; Accepted 24 December 2013; Published 20 February 2014

Copyright © 2014 Francesca Capone et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hepatocellular carcinoma is the fifth most common cancer worldwide and shows a complex clinical course, poor response to pharmacological treatment, and a severe prognosis. Thus, the aim of this study was to investigate whether tacrolimus (FK506) has synergistic antitumor effects with doxorubicin on two human hepatocellular carcinoma cell lines, Huh7 and HepG2. Cell viability was analyzed by Sulforhodamine B assay and synergistic effect was evaluated by the software CalcuSyn. Cell apoptosis was evaluated using Annexin V and Dead Cell assay. Apoptosis-related protein PARP-1 cleaved and autophagy-related protein expressions (Beclin-1 and LC3B) were measured by western blotting analysis. Cytokines concentration in cellular supernatants after treatments was studied by Bio-Plex assay. Interestingly the formulation with doxorubicin and tacrolimus induced higher cytotoxicity level on tumor cells than single treatment. Moreover, our results showed that the mechanisms involved were (i) a strong cell apoptosis induction, (ii) contemporaneous decrease of autophagy activation, understood as pro-survival process, and (iii) downregulation of proinflammatory cytokines. In conclusion, future studies could relate to the doxorubicin/tacrolimus combination effects in mice models bearing HCC in order to see if this formulation could be useful in HCC treatment.

1. Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, and more than half a million new cases occur annually. HCC generally develops from chronic liver injury, which leads to inflammation, hepatocyte regeneration, liver matrix remodeling, fibrosis, and, finally, cirrhosis [1]. The main risk factors for HCC are hepatitis B (HBV) or C virus (HCV) infection, alcohol-induced liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), primary biliary cirrhosis, exposure to environmental carcinogens (particularly aflatoxin), and then type 2 diabetes and obesity [2]. Less common causes include hereditary hemochromatosis, alphal-antitrypsin deficiency, autoimmune hepatitis, some porphyrias, and Wilson’s disease. The distribution of these risk factors among patients with HCC is highly variable, depending on geographic region and race or ethnic group [3]. Although the clinical diagnosis and management of early-stage HCC have improved significantly, its prognosis is still extremely poor [4]. However, this cancer is often diagnosed at an advanced stage when most potentially curative therapies such as resection, transplantation or percutaneous, and transarterial interventions are of limited efficacy and no response is obtained to common therapies. Therefore, new effective and well-tolerated therapy strategies are urgently needed [5, 6]. Chemotherapy is one of the common strategies in HCC treatment, especially for unresectable tumors. Doxorubicin (adriamycin, DOX), antineoplastic chemotherapy drug that is a standard component in treating advanced HCC for its antitumor action, has shown insufficient efficacy, with a response rate of about 15–20% [7]. Other chemotherapeutics, such as epirubicin, cisplatin, 5-fluorouracil, and etoposide and their combinations, demonstrate even lower efficacy [8]. Combined therapy with multiple drugs or modalities
is a common practice in the cancer treatment, which can achieve better therapeutic effects than a single drug or modality and can reduce the side effects and resistance to drugs [1]. In fact, it is well known that the cancer is a biological multicellular entity consisting of a heterogeneous population of tumor cells, multiple variety of cell types and normal infiltrating lymphocytes and their communication is bidirectional and dynamic. Therefore, a neoplasia can be defined as a pathological condition resulting from the interaction between tumor and microenvironment in which the latter affects the neoplastic cells growth and their ability to metastasize [9, 10]. Hence, to obtain a new antitumor strategy it is necessary to consider the microenvironment in which the tumor originates and to define the mechanisms that govern the control of immune responses in order to concern the opportunity to use the immunotherapy together with the current cancer therapies. For these reasons, the aim of this study was to combine the doxorubicin with an immunosuppressive agent which could simultaneously both act as an immunosuppressive agent and enhance the chemotherapeutic effectiveness exhibiting antitumor properties. Tacrolimus (FK506) is a macrolide produced by Streptomyces tsukubaensis that has shown antiproliferative effects in vitro [11]. Moreover, it has been already used, in patients undergoing orthotopic liver transplantation, as an immunosuppressant able to block the T-cell activation by calcineurin [12]. We have chosen to evaluate the effects of these molecules on two human liver cancer cell lines, Huh7 and HepG2, because our aim is to focus on liver cancer and immune modulation in order to metastasize [9, 10]. Hence, to obtain a new antitumor strategy it is necessary to consider the microenvironment in which the tumor originates and to define the mechanisms that govern the control of immune responses in order to concern the opportunity to use the immunotherapy together with the current cancer therapies. For these reasons, the aim of this study was to combine the doxorubicin with an immunosuppressive agent which could simultaneously both act as an immunosuppressive agent and enhance the chemotherapeutic effectiveness exhibiting antitumor properties. Tacrolimus (FK506) is a macrolide produced by Streptomyces tsukubaensis that has shown antiproliferative effects in vitro [11]. Moreover, it has been already used, in patients undergoing orthotopic liver transplantation, as an immunosuppressant able to block the T-cell activation by calcineurin [12]. We have chosen to evaluate the effects of these molecules on two human liver cancer cell lines, Huh7 and HepG2, because our aim is to focus on liver cancer and metastasis [9, 10]. Hence, to obtain a new antitumor strategy it is necessary to consider the microenvironment in which the tumor originates and to define the mechanisms that govern the control of immune responses in order to concern the opportunity to use the immunotherapy together with the current cancer therapies.

2. Methods

2.1. Cell Culture and Treatments. Human hepatocellular carcinoma cell lines Huh7 and HepG2 (Lonza, Verviers, Belgium) were kept in culture and expanded at 37°C in a humidified atmosphere of 5% CO₂ in culture medium DMEM (Dulbecco's Modified Eagle's Medium, Lonza), supplemented with FBS (Invitrogen, Camarillo, CA, USA) at 10%, penicillin/streptomycin 100× (Euroclone, Devon, UK), glutamax 100× (Invitrogen), and nonessential amino acids 100× (Invitrogen). Phosphate buffer (PBS phosphate buffered saline Ca²⁺ and Mg²⁺ free) and trypsin (Ca²⁺ and Mg²⁺ free) were supplied by Euroclone. The cells were plated 2×10⁶ for well in 96-well tissue culture plates and allowed to attach for 24 h. Experiments were initiated when the cells reached 80% confluence. The cells were treated with doxorubicin (Ebewe Pharma, Unterach am Attersee, Austria) and tacrolimus (FK506) (registered trademark Prograf, Astellas Pharma Inc., TYO: 4503, Japan) for 48 h. The drugs were dissolved in DMEM supplemented with 1% FBS at concentrations of 0.21, 0.42, 0.85, 1.7, 3.4, and 6.8 μM and 0.013, 0.026, 0.052, 0.1, 0.2, and 0.4 μM, respectively, for Huh7 treatment, while the drugs were dissolved in DMEM supplemented with 1% FBS at concentrations of 0.09, 0.18, 0.37, 0.75, 1.5, and 3 μM for doxorubicin and 0.002, 0.006, 0.047, 0.095, 0.18, and 0.36 nM for tacrolimus during HepG2 treatment. Subsequently according to the results, combination treatment (cotreatment) with doxorubicin and tacrolimus was carried out at IC50 (the median inhibitory concentration defined as the drug concentration at which cell growth was inhibited by 50%) doses obtained for 48 h.

2.2. Colorimetric Assay with Sulforhodamine B. After 48 h of drugs exposition, cell survival/proliferation was measured in presence and absence of drugs in 96-well plates by a spectrophotometric dye incorporation assay using Sulforhodamine B (SRB). Cells were fixed with trichloroacetic acid (Sigma Aldrich, St. Louis, MO, USA) for 1 h and after stained for 30 min with 0.4% (wt/vol) SRB (Sigma Aldrich) dissolved in 1% acetic acid. The number of viable cells was directly proportional to the protein bound-dye formation which was then solubilized with 10 mM Tris base solution pH 10.5 and measured by fluorometric assay ELISA at 540 nm (Bio-Rad, Hercules, CA, USA; Microplate Reader). All experiments were performed in duplicate and were repeated for three times [16]. The IC50 was assessed from the dose-response curves.

2.3. Drug Combination Studies. Drug combination studies were based on concentration-effect curves generated as a plot of the fraction of unaffected (surviving) cells versus the drug concentration after 48 h of treatment. Briefly, individually and in combination equiactive doses (50:50 cytotoxic ratio) of the two drugs (IC50) were tested for 48 h. Synergism, additivity, and antagonism were quantified by determining the CI (combination index) calculated by the Chou-Talalay equation and with the software CalcuSyn (Biosoft, Cambridge, UK) [17]. Assuming 0.9 as the cutoff, CI < 0.9, CI(1/4)0.9–1, or CI > 1 indicates synergistic, additive, or antagonistic effects, respectively. The dose reduction index (DRI) represents the measure of how much the dose of each drug in a synergistic combination may be reduced at a given effect level compared with the dose of each drug alone. The linear correlation coefficient (r) of the median-effect plot is considered a conformity measure of the data according to the mass-action law principle when the experimental measurement is assumed to be accurate. An r value equal to 1 indicates perfect conformity while a poor value may be the result of biological variability or experimental deviations. For all our experiments r values were between 0.91 and 0.98 indicating a good data conformity.
2.4. Apoptosis Detection. The cells (1 × 10^6) were harvested and washed twice with ice-cold PBS. Subsequently, the cells were labeled with Annexin V and Dead Cell assay kit according to the manufacturer’s instructions (Merck Millipore, Darmstadt, Germany). This assay is based on the phosphatidylserylne (PS) detection on the apoptotic cells surface, using fluorescently labeled Annexin V in combination with the dead cell marker, 7-Aminoactinomycin D (7-AAD). We calculated the apoptotic ratio by identification of four populations: (i) viable cells, not undergoing detectable apoptosis: Annexin V (−) and dead cell marker (−), (ii) early apoptotic cells: Annexin V (+) and dead cell marker (−), (iii) late apoptotic cells: Annexin V (+) and dead cell marker (+), and (iv) cells that have died through nonapoptotic pathway: Annexin V (−) and dead cell marker (+). The samples were determined by the Muse Cell Analyzer (Merck Millipore) and analyzed by software provided by Merck Millipore.

2.5. Protein Extraction and Western Blotting. Cells were washed once in cold phosphate buffered saline (PBS) and lysed in a lysis buffer containing 50 mM N-(2-hydroxyethyl)piperazine-N’-2-ethanesulfonic acid, 150 mM NaCl, 1 mM ethylenediamine tetra-acetic acid, 1 mM ethylene glycol tetra-acetic acid, 10% glycerol, 1% Triton-X-100, 1 mm phenylmethylsulfonyl fluoride, 1 μg aprotinin, 0.5 mm sodium orthovanadate, and 20 mM sodium pyrophosphate. The lysates were clarified by centrifugation at 16,000 g for 10 min. Protein concentrations were estimated by a BioRad assay (BioRad) and boiled in Laemmli buffer (Tris-HCl 0.125 m pH 6.8, sodium dodecyl sulphate (SDS) 4%, glycerol 20%, 2-mercaptoethanol 10%, bromophenol blue 0.002%) for 5 min before electrophoresis. Proteins were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) (15% polyacrylamide) under reducing condition. After electrophoresis, proteins were transferred to nitrocellulose membranes (Immobilon-P Millipore Corp., Bedford, MA, USA); complete transfer was assessed using prestained protein standards (BioRad). After blocking with Tris-buffered saline- (TBS-) bovine serum albumin (BSA) (25 mm Tris, pH 7.4, 200 mm NaCl, 5% BSA), the membranes were incubated with the specific primary anti-human antibodies against Beclin-1 (BECNI) 1:500 (Cell Signaling Technology, Inc. Beverly, Massachusetts), LC3B 1:500 (Cell Signaling Technology), and PARP-1 1:500 (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) overnight at 4°C. When the membranes were washed and incubated with anti-rabbit horseradish peroxidase conjugate at a dilution of 1:3000 for 1 h at room temperature, the immunoreactive bands of proteins were visualized by enhanced chemiluminescence immunoassay method (ECL Amersham Biosciences, Little Chalfont, UK). The blots were stripped and reprobed with anti-GAPDH antibody (Santa Cruz Biotechnology) to normalize for differences in protein loading.

2.6. Cytokine Evaluations by Bio-Plex Assay. A multiplex biometric ELISA-based immunoassay, the Luminex platform (Bio-Plex, Bio-Rad Lab), containing dyed microspheres conjugated with a monoclonal antibody specific for a target protein was used, according to the manufacturer’s instructions (Bio-Plex, Bio-Rad Lab) to evaluate the trends and the concentrations of different soluble molecules in cellular supernatants. After 48 h of incubation with the drugs, used alone or in combination, some cytokines chemokines and growth factors were measured using Human Cytokine 27 Plex Panel (Bio-Plex, Bio-Rad Lab). In particular, we evaluated PDGF-ββ, IL-1β, IL-1α, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF basic, G-CSF, GM-CSF, INF-γ, IP-10, MCP-1, MIP-1α (CCL3), MIP-1β (CCL4), Rantes, TNF-α, and VEGF. Each experiment was performed in duplicate as previously described [16, 18, 19]. Protein concentrations were determined using a Bio-Plex array reader (Luminex, Austin, TX) that quantifies multiplex immunoassays in a 96-well plate with very small fluid volumes. The analyte concentration was calculated using a standard curve, with software provided by the manufacturer (Bio-Plex Manager Software).

2.7. Bioinformatics Analysis. The cytokines concentrations evaluated in treated versus untreated Huh7 were compared by t-test using the statistical program Prism 4 (GraphPad Software, San Diego, CA, USA). Values of 𝑃 < 0.05 were considered to be statistically significant. Moreover, the possible interactions between the significant proteins were analyzed by Ingenuity Pathway Analysis.

3. Results and Discussion

3.1. Cytotoxicity Assay. The cytotoxic effects of doxorubicin and tacrolimus were evaluated on Huh7 and Hepg2 cell lines by SRB assay to identify the concentrations at which cell growth was inhibited by 50%. After 48 h of treatment with doxorubicin and tacrolimus, compared to nontreated cells, Huh7 reached IC50 at 1.1 μM and 0.07 μM doses and HepG2 reached IC50 at 0.72 μM and 0.047 nM doses, respectively (Figures 1(a) and 1(b)). These results indicate that tacrolimus has stronger effect than doxorubicin in inhibiting cell growth of both cell lines tested. By comparison, the IC50 values of both drugs in HepG2 cells were lower than in Huh7 cells. These results suggest that HepG2 cells were more sensitive to these drugs than Huh7 cells. All experiments were performed in triplicate; values were analyzed and presented as means ± standard deviation (SD). Subsequently we evaluated the synergistic antitumor effects of doxorubicin in combination with tacrolimus. Taking advantage of the median drug effect analysis in calculating combination indexes (CIs), we explored the antiproliferative effects of doxorubicin and tacrolimus combinations by testing equipotent doses of the two agents (50:50 cytotoxic ratio). A strong synergistic effect with low CIs (CIs < 0.9) was demonstrated when simultaneous equipotent combination doses were used for both cell lines, Huh7 and HepG2 (Figures 2(a) and 2(b); Table 1). In addition, as visible in Table 1, we obtained after the combination treatment a dose reduction in the IC50 values (DR150) of 5.84-fold for doxorubicin and of 21.15-fold for tacrolimus in Huh7 cells and a DR150 of 3.35-fold for doxorubicin and of 3.88-fold for tacrolimus in HepG2 cells.
3.2. Apoptosis Studies. Subsequently we investigated the ability of doxorubicin, tacrolimus, and their combination to induce apoptosis in Huh7 and HepG2 cells. Simultaneous treatment with concentrations below the IC50 values of doxorubicin (0.85 μM in Huh7 cells; 0.37 μM in HepG2 cells) and tacrolimus (0.052 μM in Huh7 cells; 0.006 nM in HepG2 cells) induced a synergistic apoptotic effect (Tables 2(a) and 2(b)).

In the Tables 2(a) and 2(b) are shown the percentages of the four populations described in Material and Methods Section. These results were further confirmed by western blotting analysis, showing PARP-1 cleavage induction in doxorubicin and combined treatments and only barely detectable correspondent bands after tacrolimus treatment in Huh7 and HepG2 cells (Figure 3).

3.3. Autophagy Markers Evaluation. Subsequently we analyzed the autophagy-related hallmarks expression: Beclin-1 (BECN1) and LC3B. Beclin-1 is constitutively expressed in Huh7 and in HepG2 cells (as shown in Figure 3) and participates, together with LC3B-II, in the autophagosome development [20]. In particular, the conversion of LC3B-I to LC3B-II form has been used as indicator of autophagy activation. Based on our result, autophagy may contribute to the survival of HCC during doxorubicin and tacrolimus cotreatment.
Table 1: Doxorubicin and tacrolimus cotreatment induced a synergistic antiproliferative effect compared to treatment with drugs administered individually as demonstrated by median drug effect analysis calculating the combination index (CI) and the dose reduction index (DRI) with CalcuSyn software. \( r \) is the linear correlation coefficient.

| Cell line | Treatment | CI \(_{50} (\pm SD)\) | \( r (\pm SD) \) | DRI (dox) | DRI (tacr) |
|-----------|-----------|------------------------|----------------|-----------|-----------|
| Huh7      | dox + tacr| 0.22 ± 0.03            | 0.96 ± 0.01    | 5.84 ± 0.06 | 21.15 ± 3.12 |
| HepG2     | dox + tacr| 0.55 ± 0.03            | 0.98 ± 0.008   | 3.35 ± 0.08 | 3.88 ± 0.05 |

**Figure 3:** PARP-1 cleaved, Beclin-1, LC3I, and LC3II protein expression analysis by western blotting in Huh7 and HepG2 cell lines after treatment with doxorubicin (0.85 \( \mu M \)) and tacrolimus (0.052 \( \mu M \)) and cotreatment (0.42 \( \mu M \) dox plus 0.026 \( \mu M \) tacr). GAPDH was used as loading control.

Table 2: Percentage of live, early apoptotic, late apoptotic, and dead cells by the Muse Annexin V and Dead Cell assay in Huh7 (a) and HepG2 (b) cell lines.

| (a) | CTRL | TACR | DOX | Cotreat |
|-----|------|------|-----|---------|
| Live | 83.34% | 31.57% | 9.39% | 0.81% |
| Early apoptosis | 11.42% | 54.18% | 1.46% | 0.52% |
| Late apoptosis | 4.95% | 14.25% | 88.96% | 98.66% |
| Dead | 0.28% | 0% | 0.20% | 0% |

| (b) | CTRL | TACR | DOX | Cotreat |
|-----|------|------|-----|---------|
| Live | 70.29% | 42.18% | 11.51% | 3.72% |
| Early apoptosis | 16.70% | 28.27% | 57.07% | 11.62% |
| Late apoptosis | 12.40% | 26.96% | 30.43% | 84.45% |
| Dead | 0.65% | 2.61% | 1.00% | 0.21% |

treatment. In fact cell death was accompanied by a marked proliferation of autophagosomal-lysosomal compartments shown by evident Beclin-1 and LC3B-II bands in both cell lines (Figure 3). On the other hand, during cotreatment there was downregulation of Beclin-1 and upregulation of LC3B-II, being index of autophagy, and we also observed a more enhanced cell death [21, 22].

The mechanism of cell death induced by doxorubicin is discussed in the literature. Doxorubicin induced apoptosis in hepatoma cell lines HepG2 and Bel7402 at concentration of 1.25 mg/L and in Morris Hepatoma cells at concentration of 1 \( \mu M \) [23]. Among the possible cell death mechanisms suggested there is autophagy [8]. Autophagy is an essential and conserved process, through which intact organelles and/or large portions of the cytoplasm are engulfed within double-membraned autophagic vacuoles for degradation, and may be dysregulated in metabolic diseases, neurodegenerative disorders, infectious diseases, and cancer [24]. However, even if basal levels of autophagy ensure the physiological turnover of old and damaged organelles, the massive accumulation of autophagic vacuoles may represent either an alternative pathway of cell death or an ultimate attempt for cells to survive by adapting to stress. In these instances, autophagy operates as a prosurvival mechanism [25]. On the other hand, in the literature it is reported that tacrolimus significantly inhibited the growth of poorly differentiated cell line of HLE and its cytotoxicity was characterized by G0/G1 phase cell cycle arrest [26]. Moreover, it induced cell death of Jurkat human T lymphocytes by apoptosis in dose- and
Figure 4: Significant cytokine levels (pg/mL) evaluated in cellular supernatant untreated and after treatment with doxorubicin (0.85 μM) and tacrolimus (0.052 μM) and cotreatment (0.42 μM dox plus 0.026 μM tacr).
time-dependent manners characterized by nuclear fragmentation and caspase 3 protease activation [12]. It also induced apoptosis by immunosuppression mechanism in T cells [27], produced concentration dependent antiproliferative effect in SMMC-7721 cells (1–100 ng/mL), and its pretreatment for 2 hours enhanced the effect of another drug, the 5-FU, on the induction of apoptosis [11]. Our results showed that during the co-treatment there is a blockage of autophagy. Therefore, the autophagy could be interpreted as a survival mechanism put in place by cells to maintain their function and their viability when they are in conditions of deprivation of energy [21].

3.4. Cytokine Evaluations and Interactomic Studies. Then, we evaluated the cytokines levels in Huh7 cellular supernatants after 48 h of incubation with drugs alone and in combination with concentrations below the IC50 values of doxorubicin (0.85 µM) and tacrolimus (0.052 µM) by Bio-Plex assay.

The results obtained were compared with untreated cells used as control. These experiments showed that the levels of proinflammatory cytokines, such as IL-1β, IL-7, IL-8, VEGF, and TNF-α decreased in statistically significant way, with P values < 0.05, both with drug alone rather than cotreatment (Figure 4). Similar results were also obtained for the HepG2 cells (data not shown).

These proteins are strictly involved in HCC. In fact, IL-1β is a cytokine that promotes inflammatory processes, stimulating the production of cytokines and the recruitment of other immune system cells and has been found increased in patients with chronic liver disease [28]. IL-8 is a proinflammatory chemokine (CXCL8) that has strong proangiogenic activity in HCC patients and is upregulated by IL-7 [29, 30]. TNF-α plays an important role in apoptosis, in
proliferation, in cell differentiation, and in viral replication, and its high expression levels in HCC induce the promotion of cell survival and tumor progression [31, 32]. VEGF is a growth factor upregulated in HCC [33].

Then, the five significant cytokines were analyzed by Ingenuity Pathway Analysis 7.1 (Ingenuity Systems, Inc., Redwood City, CA, USA) that generates networks on the basis of associated functions and data mining from experimental data reported in the literature. Interactomics studies on these cytokines were performed by IPA software. It creates networks between the selected proteins extracting information related to biological correlations from databases that collect experimental data and scientific published papers. The user can insert as input for the research only a list of genes/proteins and not other information like cell types. Our molecules have been found involved into a network named “Cell-To-Cell Signaling and Interaction, Hematological System Development and Function, Immune Cell Trafficking” (Figure 5).

In detail, five significant molecules are connected with some hub proteins, such as NF-κB and its RELA subunit (NF-κB/p65), STAT3 (signal transducer and activator of transcription 3), and ZFP36 (zinc finger protein 36) that are involved in HCC. In fact, in literature it is reported that (i) ZFP36 is responsible for inducing an increase of cell motility and invasiveness in this cancer [31], (ii) STAT3 activation accelerates liver cancer progression [34], and (iii) NF-κB signaling activation induces also HCC metastasis [35]. In detail, in the obtained network, ZFP36 interacts with TNF-α interfering with its production by destabilizing its mRNA [36]. STAT3 interacts with IL-8, TNF-α, and VEGF by modulating their expression [37]. Finally, NF-κB and its subunit, RELA, are correlated with IL-1, IL-8, and TNF-α that interacts with IL-7 creating a heterodimer that contains also their receptors. Moreover, it is very interesting that RELA interacts also with BECN1; in fact, it modulates its transcription and autophagy upregulating BECN1 mRNA and protein levels in different cellular systems [38]. Overall the obtained network shows that five cytokines as well as BECN1 correlated with interesting hub nodes, like NF-κB complex, evidencing that the decrease of their levels can induce NF-κB inactivation able to block HCC development, progression, and metastasis.

In conclusion, our results have shown that doxorubicin and tacrolimus inhibit the growth of both hepatocellular carcinoma cell lines, Huh7 and HepG2, in a dose-dependent manner and their combination induces a more cytotoxic effect. Therefore, we suggest that the mechanisms involved could be a apoptosis induction, contemporaneous decrease of autophagy activation, understood as prosurvival process and immunosurveillance decrement, as well as downregulation of cytokine production. Moreover, it is important to underline that the concentrations used during the cotreatment were lower than IC50 obtained by dose-response assays with each drug treatment. In conclusion, our results indicate that tacrolimus in combination with doxorubicin is expected to be a support drug in HCC treatment. However, these experiments were obtained on cell lines and future studies will regard in vivo experiments to verify if the doxorubicin/tacrolimus combination can have effects in mice models. Until now, there are few studies in this field; in fact, it is resulted in that doxorubicin has improved antitumor activity both in vitro and in vivo with much reduced side effects [39], whereas berberine in combination with doxorubicin suppresses growth of murine melanoma B16F10 xenograft [40].

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Francesca Capone and Eliana Guerriero have contributed equally to this work.

Acknowledgment

The authors thank Dr. Marilina Russo (INT Pascale, CROM) for the help in preparing the figures.

References

[1] L.-L. Fan, G.-P. Sun, W. Wei et al., “Melatonin and Doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines,” World Journal of Gastroenterology, vol. 16, no. 12, pp. 1473–1481, 2010.
[2] S. Costantini, F. Capone, E. Guerriero et al., “Cytokine profile of patients with type 2 diabetes/or chronic hepatitis C infection,” PLoS One, vol. 7, Article ID e39486, 2012.
[3] H. B. El-Serag and K. L. Rudolph, “Hepatocellular carcinoma: epidemiology and molecular carcinogenesis,” Gastroenterology, vol. 132, no. 7, pp. 2557–2576, 2007.
[4] S.-L. Ye, T. Takayama, J. Geschwind, J. A. Marrero, and J.-P. Bronowicki, “Current approaches to the treatment of early hepatocellular carcinoma,” The Oncologist, vol. 15, pp. 34–41, 2010.
[5] M. Heuer, T. Benkö, V. R. Cinccinati et al., “Effect of low-dose rapamycin on tumor growth in two human hepatocellular cancer cell lines,” Transplantation Proceedings, vol. 41, no. 1, pp. 359–365, 2009.
[6] M. Cervello, D. Bachvarov, N. Lampiasi et al., “Molecular mechanisms of sorafenib action in liver cancer cells,” Cell Cycle, vol. 11, pp. 2843–2855, 2012.
[7] W. Yeo, T. S. Mok, B. Zee et al., “A randomized phase III study of doxorubicin versus cisplatin/interferon-α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma,” Journal of the National Cancer Institute, vol. 97, no. 20, pp. 1532–1538, 2005.
[8] I. Manov, Y. Pollak, R. Broneshter, and T. C. Iancu, “Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib—The role of extracellular signal-regulated kinase counteraction,” FEBS Journal, vol. 278, no. 18, pp. 3494–3507, 2011.
[9] A. Mantovani, P. Romero, A. K. Palucka, and F. M. Marincola, “Tumour immunity: effector response to tumour and role of the
microenvironment," *The Lancet*, vol. 371, no. 9614, pp. 771–783, 2008.

[10] S. Costantini, F. Capone, E. Guerriero, and G. Castello, "An approach for understanding the inflammation and cancer relationship," *Immunology Letters*, vol. 126, no. 1-2, pp. 91–92, 2009.

[11] X.-W. Cao, Z.-R. Fu, and G.-S. Ding, "Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721," *Hepatobiliary and Pancreatic Diseases International*, vol. 4, no. 2, pp. 269–273, 2005.

[12] S. J. N. Choi, H. S. You, and S. Y. Chung, "Tacrolimus-induced apoptotic signal transduction pathway," *Transplantation Proceedings*, vol. 40, no. 8, pp. 2734–2736, 2008.

[13] H. Nishikawa and Y. Osaki, "Non-B, non-C hepatocellular carcinoma," *International Journal of Oncology*, vol. 43, pp. 1333–1342, 2013.

[14] F. Rusolo, B. Pucci Colonna G et al., "Evaluation of selenite effects on selenoproteins and cytokinome in human hepatoma cell lines," *Molecules*, vol. 1, pp. 2549–2562, 2013.

[15] S. Costantini, G. di Bernardo, M. Cammarota et al., "Gene expression signature of human HepG2 cell line," *Gene*, vol. 518, pp. 335–345, 2013.

[16] E. Guerriero, A. Sorce, F. Capone et al., "Effects of lipoic acid, caffeic acid and a synthesized lipoyl-caffeic conjugate on human hepatoma cell lines," *Molecules*, vol. 16, no. 8, pp. 6365–6377, 2011.

[17] T.-C. Chou, "Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies," *Pharmacological Reviews*, vol. 58, no. 3, pp. 621–681, 2006.

[18] F. Capone, S. Costantini, E. Guerriero et al., "Serum cytokine levels in patients with hepatocellular carcinoma," *European Cytokine Network*, vol. 21, no. 2, pp. 99–104, 2010.

[19] S. Costantini, F. Capone, E. Guerriero, P. Maio, G. Colonna, and G. Castello, "Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis," *European Cytokine Network*, vol. 21, no. 4, pp. 251–256, 2010.

[20] Y.-H. Shi, Z.-B. Ding, J. Zhou, S.-J. Qiu, and J. Fan, "Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma," *Autophagy*, vol. 5, no. 3, pp. 380–382, 2009.

[21] K. Degenhardt, R. Mathew, B. Beaudoin et al., "Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorgenesis," *Cancer Cell*, vol. 10, no. 1, pp. 51–64, 2006.

[22] J. A. Muñoz-Gámez, J. M. Rodríguez-Vargas, R. Quiles-Pérez et al., "PARP-1 is involved in autophagy induced by DNA damage," *Autophagy*, vol. 5, no. 1, pp. 61–74, 2009.

[23] A.-C. Piguet, D. Semela, A. Keogh et al., "Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma," *Journal of Hepatology*, vol. 49, no. 1, pp. 78–87, 2008.

[24] D. C. Rubinsztain, P. Codogno, and B. Levine, "Autophagy modulation as a potential therapeutic target for diverse diseases," *Nature Reviews Drug Discovery*, vol. 11, pp. 709–730, 2012.

[25] L. Galluzzi, J. M. Vicencio, O. Kepp, E. Tasdemir, M. C. Mairui, and G. Kroemer, "To die or not to die: that is the autophagic question," *Current Molecular Medicine*, vol. 8, no. 2, pp. 78–91, 2008.

[26] M. Sakai, H. Miyake, S. Tashiro, Y. Okumura, and H. Kido, "Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells," *The Journal of Medical Investigation*, vol. 51, no. 1-2, pp. 63–69, 2004.